Q-omics provides the consensus-scored GAPDHP63 profile across patient tissues and cancer cell-line models. GAPDHP63 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, GAPDHP63 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, GAPDHP63 RNA expression shows 15,838 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, KIRC, and THYM as cancer lineages where GAPDHP63 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP63 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP63 survival associations across molecular data types. GAPDHP63 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP63 RNA expression–survival associations across cancer types. High GAPDHP63 expression shows unfavorable associations in KICH, MESO, KIRP, LIHC and LUAD, but favorable associations in READ. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for GAPDHP63 RNA expression.
This table summarizes GAPDHP63 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP63. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP63 shows higher tumor expression in KIRC, KIRP, LIHC, LUSC, LUAD and COAD. The KIRC box plot shows higher GAPDHP63 RNA expression in tumor versus normal tissue (log2 FC = +0.846, t-test p < 0.001).
This table shows molecular features associated with GAPDHP63 in patient tissues and cancer cell lines. In patient samples, GAPDHP63 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
